首页 | 本学科首页   官方微博 | 高级检索  
     

康莱特加同步放化疗治疗局部晚期非小细胞肺癌临床研究
引用本文:张旭红,杨洪叶. 康莱特加同步放化疗治疗局部晚期非小细胞肺癌临床研究[J]. 中国冶金工业医学杂志, 2009, 26(5): 512-514
作者姓名:张旭红  杨洪叶
作者单位:1. 抚顺市第四医院放疗科,辽宁抚顺,113123
2. 辽宁能港发电有限公司职工医院
摘    要:目的:观察康莱特注射液(KLT)联合同步放化疗对局部晚期非小细胞肺癌的治疗效果。方法:48例局部晚期非小细胞肺癌患者,随机分为两组,综合组:25例,采用盖诺+顺铂方案同步放化疗,放疗予常规分割,2Gy/f,总量56~60Gy,同时加用康莱特注射液200ml/d静脉滴入,21天为1个疗程,共2个疗程。对照组:23例,采用盖诺+顺铂方案同步放化疗。2疗程后评价疗效,通过KPS评分、体重变化观察生存质量改善情况。结果:两组完全缓解率分别为20.0%和13%(P〉0.05);有效率分别为80.0%和69.5%(P〉0.05);综合组3级以上骨髓抑制发生率为40.0%,而对照组为69.6%(P〈0.05);综合组3级以上消化道不良反应发生率为8.0%,对照组为34.8%(P〈0.05);综合组无3级以上放射性肺炎发生,而对照组为4.4%(P〉0.05);综合组3级以上放射性食管炎发生率16.0%,对照组为43.5%(P〈0.05);综合组治疗前后KPS评分及体重评分明显高于对照组(P〈0.05)。结论:康莱特联合同步放化疗可以减轻放化疗引起的胃肠道反应,减少3级以上骨髓抑制和3级以上放射性食管炎的发生,使患者的生存质量得到改善,但从疗效分析,NP方案同步放化疗是否联合使用康莱特,无统计学差异。

关 键 词:康莱特注射液  同步放化疗  非小细胞肺癌

Kanglaite injection combined with concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer
ZHANG Xu-hong,YANG Hong-ye. Kanglaite injection combined with concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer[J]. Chinese Medical Journal of Metallurgical Industry, 2009, 26(5): 512-514
Authors:ZHANG Xu-hong  YANG Hong-ye
Affiliation:ZHANG Xu hong , YANG Hong-ye.( Department of Radiation Chleology, The forth Hospital ,Fushun 113123)
Abstract:Objective:To evaluate the clinical toxicity and efficacy of Kanglaite injection combined with concurrent chemora-diotherapy in the treatment of locally advanced non-small cell lung cancer.Methods:Forty-eight patients with locally advanced non-small cell lung cancer were randomized into two groups.The combination group received chemotherapy of NVB+DDP regimen,radio-therapy was given with conventional fraction in 2Gy per fraction and five fractions per week.The total tumor doses were 56~60Gy.Combined with Kanglaite injection 200 ml/d for consecutive twenty-one days for two courses, and the control group was chemoradiother-apy only. Toxicities and effects were evaluated according to the criteria of WHO. Results; The CR in combination group and control group were 20.0% and 13% ,respectively(P〉0.05). Response rate of combination group was 80.0% and 69.5% in control group (P〉0.05). Grade 3-4 leukocytopema,grade 3--4 digestive system and grade 3-4 radiation esophagitisin combination group and control group were 40.0 % , 8.0 % , 16.0 % and 69.6 % , 34.8 % , 43.5 %, respectively(P〈0.05). KPS and bodyweight score significantly increased in combination group after the combinedtreatment (P〈0.05). Conclusions: Kanglaite injection combined with concurrent chemoradiotherapy could relieve side effects of chemo radiotherapy in the treatment of locally advanced non-small cell lung cancer,and improved life quality. Kanglaitc could increase effectiverate of locally advanced non small cell lung cancer combined with concurrent chemoradiothrapy.
Keywords:Kanglaite injection  Concurrent chemoradiotherapy  Non-small cell lung cancer
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号